clarithromycin has been researched along with ketamine in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Hagelberg, NM; Kurkinen, KJ; Laine, K; Neuvonen, PJ; Olkkola, KT; Peltoniemi, MA; Saari, TI | 1 |
| Bahl, A; Bai, J; Campen, MJ; Chai, H; Chen, C; Chen, J; Chen, X; Cheng, L; Cheng, W; Dong, Q; Easton, J; Engberg, E; Fadladdin, YAJ; Franco, PM; Gao, J; Giri, AR; Goodarzi, Z; Graves, SA; Guo, Y; Holroyd-Leduc, J; Hu, Z; Huang, IC; Hudson, MM; Ji, X; Jiang, J; Johnson, S; Kaur, N; Koivusalo, SB; Kulmala, J; Lan, Q; Leng, S; Li, Q; Li, Y; Li, Z; Liang, R; Liu, F; Liu, Y; Lowman, PE; Ma, X; Menda, Y; Mielke, N; Mulder, H; Neale, G; Ness, KK; Niaz, S; Niu, Q; Pang, H; Park, EA; Plyler, E; Qin, N; Qin, X; Qiu, H; Ren, D; Ren, J; Roach, M; Robison, LL; Roine, RP; Rothman, N; Rottman Pietrzak, KA; Sahrakorpi, N; Sanghavi, DK; Santos, C; Shallom, SJ; Song, N; Spotswood, N; Stach-Lempinen, B; Subota, A; Sun, X; Tammelin, TH; Tang, J; Walker, E; Wang, M; Wang, Z; Xie, J; Xu, J; Xue, J; Xue, M; Yang, S; Yang, Y; Yarrarapu, SNS; Yasui, Y; Yu, H; Yu, W; Zelazny, AM; Zhang, H; Zhang, J; Zhang, X; Zheng, Y; Zhu, D | 1 |
2 review(s) available for clarithromycin and ketamine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Topics: Adult; Aging; Aluminum; Alzheimer Disease; Animals; Anti-Bacterial Agents; Artemisia annua; Body Mass Index; Brain; Canada; Cancer Survivors; Cardiovascular Diseases; Child; Clarithromycin; Cohort Studies; Cricetinae; Critical Care; Cross-Sectional Studies; Deferoxamine; Dementia; Depression; Diabetes Mellitus, Type 2; Diabetes, Gestational; DNA Methylation; Drug Resistance, Bacterial; Endothelial Cells; Epigenesis, Genetic; Exercise; Female; Ferroptosis; Garlic; Genetic Loci; Genome-Wide Association Study; Humans; Intensive Care Units; Iron; Iron Chelating Agents; Ketamine; Kidney; Microbial Sensitivity Tests; Mycobacterium abscessus; Mycobacterium Infections, Nontuberculous; Neoplasms; Neuroendocrine Tumors; Neurons; Nigella sativa; Obesity; Overweight; Oxidative Stress; Plant Extracts; Praziquantel; Pregnancy; Quality of Life; Radiometry; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Research Design; Retrospective Studies; RNA, Ribosomal, 23S; Schistosoma mansoni; Schistosomiasis; Schistosomiasis mansoni; Survivors; Vehicle Emissions | 2022 |
1 trial(s) available for clarithromycin and ketamine
| Article | Year |
|---|---|
Clarithromycin, a potent inhibitor of CYP3A, greatly increases exposure to oral S-ketamine.
Topics: Adult; Analgesics; Area Under Curve; Clarithromycin; Cross-Over Studies; Drug Interactions; Female; Humans; Ketamine; Male; Pain Measurement; Protein Synthesis Inhibitors | 2010 |
3 other study(ies) available for clarithromycin and ketamine
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |